Rates of bone density testing in men initiating ADT low but rising

Reuters Health - 21/10/2020 - While bone mineral density (BMD) testing is becoming more common among men initiating androgen deprivation therapy (ADT) for prostate cancer, a Canadian study suggests that most men still are not being assessed prior to treatment. Researchers examined public health administrative claims data collected in Quebec on 22,033 men who initiated ADT from 2000 to 2015. Overall, 3,910 men (17.8%) had bone mineral density testing before they started cancer treatment. The proportion of men undergoing bone mineral density testing before treatment increased from 4.1% in 2000 to 23.4% in 2015, researchers report in the Journal of the National Comprehensive Cancer Network. "Androgen deprivation therapy is associated with loss of bone density which could lead to fractures, and bone density testing can help clinicians assess a patient's risk of fracture and identify patients who would benefit from additional monitoring or interventions to prevent...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 21 October, 202028 October, 2020